ArticleAnnals of hematology2025

Phase-1 study of vamotinib (PF-114), a 3rd generation BCR::ABL1 tyrosine kinase-inhibitor, in chronic myeloid leukaemia.

Anna Turkina et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.